Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
Jacobson Research & Pharmaceutical (2633.HK): FY20 Results Summary
Jacobson Research & Pharmaceutical (2633.HK): Recurring net profit increased steadily in the middle of fiscal year 20
Jacson Pharmaceutical Research (2633.HK): Sustainable growth has new advantages in biopharmaceuticals from a perspective
Jacobson Research Pharmaceuticals (2633.HK): Business focus shifts from generic drugs to biosimilar valuation may be boosted
Puyu Gongjin Gold* Company* Jacobson Research & Pharmaceutical (2633.HK): Proposed issuance of HK$500 million convertible bonds
Pu Jade Co., Ltd. * Jacob Research Pharmaceuticals (2633.HK): net profit for fiscal year 18 is expected to increase by 45% compared with the same period last year.
Jacobson Research Pharmaceuticals (2633.HK): Hong Kong's unique generic drug manufacturer aims to achieve rapid growth through acquisitions and mergers
Deepin* Company* Jacobson Research Pharmaceutical (2633.HK): Acquire a well-known generic drug brand
Pu Jade Co., Ltd. * Jacobson Research Pharmaceutical (2633.HK): solid performance in the first half of fiscal year 17
Jacobs Research Pharmaceutical Co., Ltd. (2633.HK) apply for new shares
Jacobson (2633.HK) IPO Research
雅各臣科研制药(2633.HK)新股短评:香港最大的非专利药供应商
雅各臣科研制药有限公司(2633.HK):新股速递
雅各臣科研制药有限公司(02633.HK):首次公开发售
No Data
No Data